CDK1 and cancer: While there has been much ongoing discussion surrounding the use of CDK1 inhibitors in cancer treatment to specifically perturb proliferation via cell cycle progression [44], our results make the novel suggestion that CDK1 targeting may be able to decrease the metastatic potential of cells.